CLAIMS

1. Use of an inhibitor of secreted Phospholipase A2 group IB (GIBsPLA2) in the manufacture of a medicament for treating a CD4-T cell immunodeficiency in a subject in need thereof, wherein the inhibitor is selected from an anti-GIBsPLA2 antibody or a soluble GIBsPLA2 receptor, and wherein the GIBsPLA2 is a protein comprising amino acid residues 23-148 of SEQ ID NO: 2 or a naturally-occurring variant thereof.
2. The use of claim 1, wherein the medicament induces or stimulates an immune response.
3. The use of claim 1, wherein the GIBsPLA2 antibody is selected from anti-GIBsPLA2 polyclonal antibodies, anti-GIBsPLA2 monoclonal antibodies, and fragments thereof which bind GIBsPLA2 selected from F(ab')2 and Fab fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (VHHs or Nanobodies), and bivalent antibody fragments (diabodies).
4. The use of claim 3, wherein the antibody is human or humanized.
5. The use of anyone of claims 1 to 4, wherein the immunodeficiency is caused by a viral or bacterial infection.
6. The use of anyone of claims 1 to 5, for treating AIDS in a HIV-infected subject.
7. The use of claim 6, to suppress or reverse HIV-mediated immunodeficiency.
8. The use of anyone of claims 1 to 4, for treating an immunodeficiency caused by a cancer.
9. The use of anyone of the preceding claims, wherein the medicament is to be administered by injection, preferably intramuscular, subcutaneous, transdermal, intravenous or intraarterial; by nasal, oral, mucosal, rectal administration or by inhalation.
10. A pharmaceutical composition comprising, in the form of an injectable liquid formulation, (i) an inhibitory antibody to GIBsPLA2 selected from anti-GIBsPLA2 polyclonal antibodies, anti-GIBsPLA2 monoclonal antibodies, and fragments thereof which bind GIBsPLA2 selected from F(ab')2 and Fab fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (VHHs or Nanobodies), and bivalent antibody fragments (diabodies), and (ii) a pharmaceutically acceptable carrier or excipient suitable for an injectable liquid formulation, and wherein the GIBsPLA2 is a protein comprising amino acid residues 23-148 of SEQ ID NO: 2 or a naturally-occurring variant thereof.
11. A method for diagnosing human CD4 T cell immunodeficiency, comprising:

(a) providing a sample containing blood or plasma from a subject, and

(b) detecting or quantifying GIBsPLA2 level or activity in the sample above a threshold, wherein the GIBsPLA2 is a protein comprising amino acid residues 23-148 of SEQ ID NO: 2 or a naturally-occurring variant thereof.

12. The use of anyone of claims 1 to 9, wherein the subject is a human.